Abstract #854: Use of a Behavioral Engagmenet Model to Improve Patient-Provider Communications: A Pilot Study of a Real Life Application in an Endocrine Practice

2016 ◽  
Vol 22 ◽  
pp. 190
Author(s):  
Saleh Aldasouqi ◽  
Christie Clipper ◽  
Stephen Berkshire ◽  
John Lopes
Keyword(s):  
Pilot Study ◽  
Real Life ◽  
Improve Patient

Retinal and choroidal blood flow variations after an endurance exercise: A real-life pilot study at the Paris Marathon

2021 ◽  
Author(s):  
Martine Mauget-Faÿsse ◽  
Nicolas Arej ◽  
Morgane Paternoster ◽  
Kevin Zuber ◽  
Sabine Derrien ◽  
...  
Keyword(s):  
Blood Flow ◽  
Pilot Study ◽  
Endurance Exercise ◽  
Real Life ◽  
Choroidal Blood Flow

scholarly journals A mixed-method pilot study to improve patient satisfaction in rural Uganda

2018 ◽  
Vol 28 (5) ◽  
pp. 615-623
Author(s):  
Emily Warren ◽  
Ethel Nankya ◽  
Janet Seeley ◽  
Sarah Nakamanya ◽  
Gershim Asiki ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Pilot Study ◽  
Mixed Method ◽  
Improve Patient Satisfaction ◽  
Improve Patient

P.05.13 THE IMPACT OF “CENTRALIZED OUTPATIENT BOOKING OFFICE” ON COLONOSCOPY OUTCOMES: A REAL-LIFE PILOT STUDY

2019 ◽  
Vol 51 ◽  
pp. e189
Author(s):  
F. Mocciaro ◽  
R. Di Mitri ◽  
E. Conte ◽  
B. Magro ◽  
A. Bonaccorso ◽  
...  
Keyword(s):  
Pilot Study ◽  
Real Life ◽  
The Impact

Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus

2020 ◽  
pp. 1098612X2093321
Author(s):  
Christopher J Scudder ◽  
Katarina Hazuchova ◽  
Ruth Gostelow ◽  
David B Church ◽  
Yaiza Forcada ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Pilot Study ◽  
Growth Factor ◽  
Insulin Dose ◽  
Diabetic Control ◽  
Insulin Like Growth Factor ◽  
Significant Change ◽  
Improve Patient

Objectives An affordable and effective treatment is needed to manage feline hypersomatotropism. The aim of this study was to assess whether treatment with oral cabergoline for 90 days in cats with hypersomatotropism and diabetes mellitus improved diabetic and insulin-like growth factor 1 (IGF-1) control. Methods This was a prospective cohort non-blinded pilot study enrolling client-owned cats with spontaneously occurring diabetes mellitus and hypersomatotropism. Cats received oral cabergoline (5–10 µg/kg q24h) for 90 consecutive days. Serum IGF-1 and fructosamine concentrations were measured on days 1, 30 and 90. Quality of life was determined using the DIAQoL-pet questionnaire on days 1 and 90. Results Nine cats were enrolled and eight completed the study. There was no significant change in the following: IGF-1 (day 1 median 2001 ng/ml [range 890–2001 ng/ml]; day 30 median 2001 ng/ml [range 929–2001 ng/ml]; day 90 median 1828 ng/ml [range 1035–2001 ng/ml]; χ2(2) = 0.667, P = 0.805); fructosamine (day 1 median 499 µmol/l [range 330–887 µmol/l], day 30 median 551 µmol/l [range 288–722 µmol/l], day 90 median 503 [range 315–851 µmol/l]; χ2(2) = 0.581, P = 0.764); or DIAQoL-pet score (median on day 1 –2.79 (range –4.62 to –0.28], median on day 90 –3.24 [range –4.41 to –0.28]; P = 0.715). There was a significant change of insulin dose (χ2(2) = 8.667, P = 0.008) with cats receiving higher insulin doses at day 90 compared with day 1 (median on day 1 was 0.98 [range 0.63–1.49] and median on day 90 was 1.56 [range 0.49–2.55] units/kg q12h; P = 0.026). Conclusions and relevance Cabergoline did not improve diabetic control or normalise insulin-like growth factor concentration, or improve patient quality of life.

scholarly journals From the Laboratory to Real Life: A Pilot Study of an Expectancy Challenge With “Heavy Drinking” Young People on Holiday

2006 ◽  
Vol 41 (3) ◽  
pp. 353-368 ◽  
Author(s):  
Jade van de Luitgaarden ◽  
Reinout W. Wiers ◽  
Ronald A. Knibbe ◽  
Brigitte J. Boon
Keyword(s):  
Pilot Study ◽  
Young People ◽  
Heavy Drinking ◽  
Real Life ◽  
Expectancy Challenge

scholarly journals ReCAP: Comparison of Independent Error Checks for Oral Versus Intravenous Chemotherapy

2016 ◽  
Vol 12 (2) ◽  
pp. 168-169 ◽  
Author(s):  
Melissa C. Griffin ◽  
Rachel E. Gilbert ◽  
Larry H. Broadfield ◽  
Anthony E. Easty ◽  
Patricia L. Trbovich ◽  
...  
Keyword(s):  
Patient Safety ◽  
Nova Scotia ◽  
Improve Patient Safety ◽  
Real Life ◽  
Community Pharmacists ◽  
The United States ◽  
Oral Chemotherapy ◽  
Cancer Center ◽  
Community Pharmacies ◽  
Improve Patient

QUESTION ASKED: In the United States, research has found that oral chemotherapy is subject to fewer safeguards than are in routine use for intravenous (IV) chemotherapy; however, less is known about the Canadian context. The objective of this study was to determine whether similar safeguards, in the form of independent checks, existed to identify potential errors related to IV and oral chemotherapy formulations in a particular cancer system. SUMMARY ANSWER: In the cancer system studied, a total of 57 systematic checks were identified for IV chemotherapy, whereas only six systematic checks were identified for oral chemotherapy. Community pharmacists were the only qualified professionals involved in independent, systematic checking of oral chemotherapy, which occurred during ordering and dispensing. METHODS: Human factors specialists conducted observations and interviews in cancer center clinics, a cancer center pharmacy, and four community pharmacies across Nova Scotia. Processes were analyzed to determine whether an independent check was performed, which qualified provider completed the check, and at what point of the process the check occurred. BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: This study had some limitations. Although there are many forms of safeguards (eg, preprinted orders), only one type of safeguard (ie, independent checks) was examined in the cancer system studied. We chose to focus on independent checks because they were observable and were defined in the cancer center’s policies. Another limitation was that just a single jurisdiction (Nova Scotia), and four community pharmacies were examined. We examined each community pharmacy in detail, and sites were chosen to be representative (eg, rural versus urban). Further, the model used to deliver oral chemotherapy in Nova Scotia is not unique; a number of other provinces share similar models. REAL-LIFE IMPLICATIONS: There is an enormous opportunity for pharmacists and other qualified professionals to take on an expanded role in improving patient safety for oral chemotherapy. Oral chemotherapy, like IV chemotherapy, is known to be potentially hazardous, but in the cancer system studied, there were dramatically fewer independent checks associated with all aspects of oral chemotherapy–related processes. Greater involvement of pharmacists, both in the clinic environment and the community, would facilitate increased systematic checking, which could improve patient safety related to oral chemotherapy. [Figure: see text]

Sign in / Sign up

Export Citation Format

Share Document